

Pablo Oppezzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9189316/publications.pdf>

Version: 2024-02-01

62
papers

1,665
citations

304602

22
h-index

315616

38
g-index

63
all docs

63
docs citations

63
times ranked

2511
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients. <i>Annals of Hematology</i> , 2022, 101, 341-348.	0.8	2
2	Overcoming the Solubility Problem in <i>E. coli</i> : Available Approaches for Recombinant Protein Production. <i>Methods in Molecular Biology</i> , 2022, 2406, 35-64.	0.4	3
3	TGF- β /SMAD Pathway Is Modulated by miR-26b-5p: Another Piece in the Puzzle of Chronic Lymphocytic Leukemia Progression. <i>Cancers</i> , 2022, 14, 1676.	1.7	5
4	AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms. <i>Blood</i> , 2021, 138, 246-258.	0.6	10
5	AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression. <i>Frontiers in Oncology</i> , 2021, 11, 634383.	1.3	15
6	Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse/human chimeric antibody as a promising targeting strategy of lung tumors. <i>International Journal of Biological Macromolecules</i> , 2021, 182, 806-814.	3.6	20
7	Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 813-824.	2.0	6
8	Distinctive IGHV gene usage and stereotyped receptors in South American patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 644-648.	0.8	5
9	Overview of High-Throughput Cloning Methods for the Post-genomic Era. <i>Methods in Molecular Biology</i> , 2019, 2025, 3-32.	0.4	7
10	Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2056-2068.	0.6	14
11	The Antigen Receptor as a Driver of B-Cell Lymphoma Development and Evolution. , 2018, , .		1
12	LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL. <i>British Journal of Haematology</i> , 2018, 182, 521-525.	1.2	10
13	Multi-Compartment and Multi-Host Vector Suite for Recombinant Protein Expression and Purification. <i>Frontiers in Microbiology</i> , 2018, 9, 1384.	1.5	10
14	S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF- κ B activity during disease progression. <i>Blood</i> , 2017, 130, 777-788.	0.6	79
15	Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2017, 102, e257-e260.	1.7	9
16	Noninfectious complications in patients with pediatric-onset common variable immunodeficiency correlated with defects in somatic hypermutation but not in class-switch recombination. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 913-922.	1.5	9
17	Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression. <i>Molecules</i> , 2017, 22, 2083.	1.7	14
18	The pathogenesis of follicular lymphoma, beyond apoptosis resistance. <i>Translational Cancer Research</i> , 2017, 6, S529-S532.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen. <i>Oncolmmunology</i> , 2016, 5, e1171434.	2.1	18
20	HSP90 inhibitors decrease AID levels and activity in mice and in human cells. <i>European Journal of Immunology</i> , 2015, 45, 2365-2376.	1.6	14
21	Dissecting chronic lymphocytic leukemia microenvironment signals in patients with unmutated disease: microRNA-22 regulates phosphatase and tensin homolog/AKT/FOXO1 pathway in proliferative leukemic cells. <i>Leukemia and Lymphoma</i> , 2015, 56, 1560-1565.	0.6	15
22	Surface localization of high-mobility group nucleosome-binding protein 2 on leukemic B cells from patients with chronic lymphocytic leukemia is related to secondary autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1115-1122.	0.6	5
23	Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. <i>Leukemia</i> , 2015, 29, 115-125.	3.3	66
24	Overcoming the Solubility Problem in E. coli: Available Approaches for Recombinant Protein Production. <i>Methods in Molecular Biology</i> , 2015, 1258, 27-44.	0.4	29
25	Overexpression of Activation-Induced Deaminase in TCL1 Mice Leads to the Development of IGHV -Mutated and -Unmutated CLL Clones That Resemble Unique Subsets of Human CLL. <i>Blood</i> , 2015, 126, 1710-1710.	0.6	0
26	Sphingosine Kinases (SK): Key Molecules Associated with the Activation, Proliferation and Ibrutinib-Induced Cell Death of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2015, 126, 1714-1714.	0.6	0
27	GALNT11 as a new molecular marker in chronic lymphocytic leukemia. <i>Gene</i> , 2014, 533, 270-279.	1.0	23
28	The Expression of Sphingosine-1 Phosphate Receptor-1 in Chronic Lymphocytic Leukemia Cells Is Impaired by Tumor Microenvironmental Signals and Enhanced by Piceatannol and R406. <i>Journal of Immunology</i> , 2014, 193, 3165-3174.	0.4	21
29	Human endogenous retrovirus np9 gene is over expressed in chronic lymphocytic leukemia patients. <i>Leukemia Research Reports</i> , 2014, 3, 70-72.	0.2	26
30	Potent and Specific Inhibition of Glycosidases by Small Artificial Binding Proteins (Affitins). <i>PLoS ONE</i> , 2014, 9, e97438.	1.1	42
31	Generation of a vector suite for protein solubility screening. <i>Frontiers in Microbiology</i> , 2014, 5, 67.	1.5	27
32	Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2013, 3, e149-e149.	2.8	37
33	Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1844-1848.	0.6	16
34	Lipoprotein lipase expression in unmutated CLL patients is the consequence of a demethylation process induced by the microenvironment. <i>Leukemia</i> , 2013, 27, 721-725.	3.3	15
35	Structure of a human IgA1 Fab fragment at 1.55 Å resolution: potential effect of the constant domains on antigen-affinity modulation. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2013, 69, 388-397.	2.5	29
36	Naturally occurring mutation affecting the MyD88 binding site of TNFRSF13B impairs triggering of class switch recombination. <i>European Journal of Immunology</i> , 2013, 43, 805-814.	1.6	14

#	ARTICLE	IF	CITATIONS
37	Origins and Consequences of AID Expression in Lymphoid Neoplasms. <i>Current Immunology Reviews</i> , 2013, 9, 72-85.	1.2	6
38	Search for an aetiological virus candidate in chronic lymphocytic leukaemia by extensive transcriptome analysis. <i>British Journal of Haematology</i> , 2012, 157, 709-717.	1.2	6
39	CCR4 expression in a case of cutaneous Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL) and in CLL patients with no skin manifestations. <i>European Journal of Haematology</i> , 2011, 87, 80-86.	1.1	6
40	Tuning different expression parameters to achieve soluble recombinant proteins in <i>E. coli</i> : Advantages of high-throughput screening. <i>Biotechnology Journal</i> , 2011, 6, 715-730.	1.8	58
41	Crystal structure of an enzymatically inactive trans-sialidase-like lectin from <i>Trypanosoma cruzi</i> : The carbohydrate binding mechanism involves residual sialidase activity. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2011, 1814, 1154-1161.	1.1	19
42	Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy. <i>Cancer Research</i> , 2011, 71, 5134-5143.	0.4	100
43	High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. <i>Blood</i> , 2010, 115, 4488-4496.	0.6	79
44	Immunoglobulin heavy chain V-D-J gene rearrangement and mutational status in Uruguayan patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 2070-2078.	0.6	8
45	Chronic Lymphocytic Leukemia Cells Bind and Present the Erythrocyte Protein Band 3: Possible Role as Initiators of Autoimmune Hemolytic Anemia. <i>Journal of Immunology</i> , 2008, 181, 3674-3683.	0.4	30
46	Structural and Kinetic Analysis of Two Covalent Sialosyl-Enzyme Intermediates on <i>Trypanosoma rangeli</i> Sialidase. <i>Journal of Biological Chemistry</i> , 2006, 281, 4149-4155.	1.6	75
47	The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. <i>Blood</i> , 2005, 106, 650-657.	0.6	121
48	Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the μ and CD79a chains. <i>Blood</i> , 2005, 105, 2933-2940.	0.6	64
49	Different isoforms of BSAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005, 105, 2495-2503.	0.6	38
50	Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. <i>Leukemia</i> , 2005, 19, 2002-2005.	3.3	35
51	Post-transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions. <i>Leukemia</i> , 2004, 18, 48-56.	3.3	23
52	Somatic mutations can lead to a loss of superantigenic and polyreactive binding. <i>European Journal of Immunology</i> , 2004, 34, 1423-1432.	1.6	13
53	Combination of LPL/ADAM29 Ratio and ZAP Expression Can Replace IGVH Sequencing in the Majority of CLL. <i>Blood</i> , 2004, 104, 1097-1097.	0.6	0
54	Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. <i>Leukemia</i> , 2003, 17, 133-137.	3.3	51

#	ARTICLE	IF	CITATIONS
55	Retention and defective assembly of the B-cell receptor in the endoplasmic reticulum of chronic lymphocytic leukaemia B cells cannot be reverted upon CD40 ligand stimulation. <i>Leukemia</i> , 2003, 17, 1196-1199.	3.3	6
56	Idiotypic-pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 243-250.	1.2	15
57	Binet's Staging System and VH Genes Are Independent but Complementary Prognostic Indicators in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 3928-3932.	0.8	76
58	Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. <i>Blood</i> , 2003, 101, 4029-4032.	0.6	109
59	Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells. <i>Leukemia</i> , 2002, 16, 2438-2446.	3.3	40
60	Tn antigen is a pre-cancerous biomarker in breast tissue and serum in nitrosomethylurea-induced rat mammary carcinogenesis. , 2000, 86, 753-759.		22
61	Production and Functional Characterization of Two Mouse/Human Chimeric Antibodies With Specificity for the Tumor-Associated Tn-Antigen. <i>Hybridoma</i> , 2000, 19, 229-239.	0.9	23
62	Molecular Cloning of a Monoclonal Anti-Tumor Antibody Specific for the Tn Antigen and Expression of an Active Single-Chain Fv Fragment. <i>Hybridoma</i> , 1997, 16, 317-324.	0.9	14